BR112023003493A2 - Uso de um composto inibidor de dhodh em terapia de câncer de combinação - Google Patents
Uso de um composto inibidor de dhodh em terapia de câncer de combinaçãoInfo
- Publication number
- BR112023003493A2 BR112023003493A2 BR112023003493A BR112023003493A BR112023003493A2 BR 112023003493 A2 BR112023003493 A2 BR 112023003493A2 BR 112023003493 A BR112023003493 A BR 112023003493A BR 112023003493 A BR112023003493 A BR 112023003493A BR 112023003493 A2 BR112023003493 A2 BR 112023003493A2
- Authority
- BR
- Brazil
- Prior art keywords
- dhodh
- inhibitor compound
- cancer therapy
- combination cancer
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070984P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/047778 WO2022047051A1 (en) | 2020-08-27 | 2021-08-26 | Use of a dhodh inhibitor compound in combination cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003493A2 true BR112023003493A2 (pt) | 2023-04-11 |
Family
ID=78000775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003493A BR112023003493A2 (pt) | 2020-08-27 | 2021-08-26 | Uso de um composto inibidor de dhodh em terapia de câncer de combinação |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230285365A1 (https=) |
| EP (1) | EP4203950B1 (https=) |
| JP (1) | JP7734742B2 (https=) |
| KR (1) | KR20230078997A (https=) |
| CN (1) | CN116847874A (https=) |
| BR (1) | BR112023003493A2 (https=) |
| CA (1) | CA3190511A1 (https=) |
| ES (1) | ES3063941T3 (https=) |
| WO (1) | WO2022047051A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211462T1 (hr) | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| JOP20210147A1 (ar) * | 2018-12-21 | 2023-01-30 | Les Laboratoires Servier Sas | صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57962B1 (sr) | 2013-02-25 | 2019-01-31 | Aurigene Discovery Tech Ltd | Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US20180369206A1 (en) * | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| HRP20211462T1 (hr) * | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| WO2020109625A1 (en) * | 2018-11-30 | 2020-06-04 | Fondazione Centro San Raffaele | Combined treatment of primary central nervous system lymphoma |
| JOP20210147A1 (ar) | 2018-12-21 | 2023-01-30 | Les Laboratoires Servier Sas | صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه |
-
2021
- 2021-08-26 ES ES21783084T patent/ES3063941T3/es active Active
- 2021-08-26 CA CA3190511A patent/CA3190511A1/en active Pending
- 2021-08-26 EP EP21783084.3A patent/EP4203950B1/en active Active
- 2021-08-26 US US18/015,396 patent/US20230285365A1/en active Pending
- 2021-08-26 BR BR112023003493A patent/BR112023003493A2/pt unknown
- 2021-08-26 CN CN202180052749.9A patent/CN116847874A/zh active Pending
- 2021-08-26 WO PCT/US2021/047778 patent/WO2022047051A1/en not_active Ceased
- 2021-08-26 KR KR1020237004006A patent/KR20230078997A/ko active Pending
- 2021-08-26 JP JP2023512718A patent/JP7734742B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN116847874A (zh) | 2023-10-03 |
| US20230285365A1 (en) | 2023-09-14 |
| WO2022047051A1 (en) | 2022-03-03 |
| JP7734742B2 (ja) | 2025-09-05 |
| KR20230078997A (ko) | 2023-06-05 |
| CA3190511A1 (en) | 2022-03-03 |
| EP4203950C0 (en) | 2026-02-18 |
| ES3063941T3 (en) | 2026-04-21 |
| EP4203950A1 (en) | 2023-07-05 |
| JP2023540206A (ja) | 2023-09-22 |
| EP4203950B1 (en) | 2026-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026519A2 (pt) | Uso de um composto inibidor de dhodh em terapia de câncer de combinação | |
| BR112023003493A2 (pt) | Uso de um composto inibidor de dhodh em terapia de câncer de combinação | |
| BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| BR112022014889A2 (pt) | Composto de sulfonamida ou sulfinamida possuindo efeito de indução de degradação da proteína brd4 e uso farmacêutico do mesmo | |
| BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
| BR112022000713A2 (pt) | Imidazopirimidinas como inibidores de eed e o uso das mesmas | |
| BR112018006039A2 (pt) | terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma | |
| BR112023006337A2 (pt) | Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer | |
| BR112017003186A2 (pt) | composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
| MX2024008115A (es) | Tratamiento conjunto para tratamiento contra el cancer. | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| WO2021041539A3 (en) | Pyrido-indole analogues as gpx4 inhibitors | |
| MX2021008010A (es) | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). | |
| BR112022001699A2 (pt) | Métodos e composições para reduzir imunogenicidade através de inibidores não deplecionais de célula b | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| BR112023025738A2 (pt) | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. |